Resistant Hypertension: Emerging Therapies And Future Directions

Abstract

Background: Resistant hypertension (RH), defined as uncontrolled blood pressure despite adherence to three optimally dosed antihypertensive medications including a diuretic, is a growing global health concern associated with increased cardiovascular and renal morbidity. The multifactorial nature of RH necessitates a comprehensive approach that extends beyond conventional pharmacotherapy.

Objective: To explore current advancements in the management of resistant hypertension, focusing on emerging pharmacological therapies, device-based interventions, and future personalized treatment strategies.

Methods: A detailed review of recent clinical trials, meta-analyses, and guideline-based recommendations was undertaken to evaluate the efficacy and safety of novel therapies for RH. Emphasis was placed on mineralocorticoid receptor antagonists, endothelin receptor antagonists, renal denervation, baroreflex activation therapy, and precision medicine tools.

Results: Spironolactone remains a cornerstone in RH management, but newer agents like finerenone offer improved tolerability. Endothelin receptor antagonists, such as aprocitentan, have demonstrated significant BP reductions in recent trials. Device-based therapies, including renal denervation and baroreflex activation, show promising outcomes in selected patient populations. Emerging technologies, including genetic profiling and machine learning algorithms, are enabling more personalized approaches to diagnosis and treatment.

Conclusion: The evolving therapeutic landscape of resistant hypertension highlights the potential of combining pharmacological innovation, interventional procedures, and personalized medicine. Future research should focus on validating these approaches in diverse populations and integrating them into standard clinical practice to improve outcomes for patients with resistant hypertension.